



# Article CLOCK Gene Variation Is Associated with the Incidence of Metabolic Syndrome Modulated by Monounsaturated Fatty Acids

Dayeon Shin <sup>1</sup> and Kyung-Won Lee <sup>2,\*</sup>

- <sup>1</sup> Department of Food and Nutrition, Inha University, Incheon 22212, Korea; dyshin@inha.ac.kr
- <sup>2</sup> Department of Home Economics Education, Korea National University of Education, Cheongju 28173, Korea
- \* Correspondence: kwlee@knue.ac.kr; Tel.: +82-62-670-2445

Abstract: The circadian locomotor output cycles kaput (CLOCK) gene plays a crucial role in regulating circadian rhythms through its transcription factor gene product. The objective of this study was to investigate the association between CLOCK rs1801260 and the incidence of metabolic syndrome modulated by dietary monounsaturated fatty acid (MUFA) intake in Korean adults. Using a dataset from the Ansan-Ansung Cohort Study of the Korean Genome and Epidemiology Study, 3608 Korean adults were included after an average of nine years of follow-up. Men who were minor allele carriers (G allele) of CLOCK rs1801260 had a 18% higher incidence of metabolic syndrome than non-carriers [hazard ratio (HR), 1.18; 95% confidence interval (CI), 1.00-1.40; p Value = 0.047]. By dichotomizing dietary MUFA intake, we observed that men who were minor allele carriers (G allele) of CLOCK rs1801260 had a 42% increased incidence of metabolic syndrome when dietary MUFA intake was  $\leq$ 3.5% (HR: 1.42, 95% CI 1.23–1.81; p Value = 0.004). No significant association was found between CLOCK rs1801260 and the incidence of metabolic syndrome modulated by dietary MUFA intake in women. CLOCK polymorphisms affected metabolic syndrome, modulated by dietary MUFA intake in men. These results suggest the significance of CLOCK genes in the pathogenesis of metabolic syndrome and the modulating role of dietary MUFA intake and provide new insights into the underlying mechanisms connecting the circadian system, dietary factors, and metabolic syndrome.

**Keywords:** *CLOCK* polymorphisms; metabolic syndrome; dietary monounsaturated fatty acids; Korean Genome and Epidemiology Study (KoGES)

## 1. Introduction

The transcription factor encoded by the circadian locomotor output cycles kaput (*CLOCK*) gene is a crucial element of the molecular circadian clock [1]. Energy balance is influenced by this transcription factor, thus impacting metabolic pathways [2]. A large body of evidence suggests that genetic variation in *CLOCK* is associated with the development of metabolic syndrome and its components [1,3,4]. Mutations in *CLOCK* genes may be a causal factor for the expression of metabolic syndrome components by altering transcriptional regulation, with *CLOCK* mutant mice showing impaired glucose tolerance [5]. Disruption of *CLOCK* genes can lead to impaired glucose tolerance and diabetes in mouse models [6].

Metabolic syndrome is affected by both genetic and dietary factors. *CLOCK* genetic polymorphisms have been associated with metabolic syndrome, and one of the most studied *CLOCK* gene polymorphisms at the 3'-untranslated region is rs1801260 [7]. Dietary factors play a key role in the development of metabolic syndrome. Consumption of dietary monounsaturated fatty acids (MUFA) promotes improved metabolic profiles such as improving insulin sensitivity, maintaining healthy blood lipid profiles and regulating blood glucose levels [8]. However, studies evaluating how *CLOCK* genetic polymorphisms predispose an individual to metabolic syndrome, and how this relationship is modulated by MUFA, are lacking.



Citation: Shin, D.; Lee, K.-W. CLOCK Gene Variation Is Associated with the Incidence of Metabolic Syndrome Modulated by Monounsaturated Fatty Acids. J. Pers. Med. 2021, 11, 412. https://doi.org/10.3390/ jpm11050412

Academic Editors: Yvonne T. van der Schouw and Diederick E. Grobbee

Received: 6 April 2021 Accepted: 7 May 2021 Published: 14 May 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Research investigating the relationship between *CLOCK* single nucleotide polymorphisms (SNPs) and the incidence of metabolic syndrome modulated by MUFA intake using a prospective cohort study design is limited, and the role of *CLOCK* SNPs in metabolic syndrome in Korean adults is unclear. Thus, the primary objective of this study was to investigate the association between the common *CLOCK* SNP rs1801260 and the incidence of metabolic syndrome in Korean adults. Additionally, we assessed the association of *CLOCK* SNP rs1801260 with the incidence of metabolic syndrome modulated by MUFA intake.

#### 2. Material and Methods

## 2.1. Study Design and Participants

Data from the Ansan-Ansung Cohort Study of the Korean Genome and Epidemiology Study (KoGES), which is an ongoing prospective study conducted by the Korea National Institute of Health, was used for this study [9]. Briefly, the Ansan-Ansung community-based cohort study began in 2001–2002 to examine the dietary and lifestyle factors that affect the incidence and prevalence of chronic diseases in the Korean population. A total of 10,030 adults, aged 40–69 years, who resided in Ansan (urban) and Ansung (rural) were recruited. The participants were followed up bi-annually, and we utilized the follow-up data until 2016.

From the 10,030 participants at baseline examination (2001–2002), participants who did not follow up at least once during the follow-up (n = 912), had no information on metabolic syndrome at baseline (n = 9), had a diagnosis of metabolic syndrome at baseline (n = 2800), had a diagnosis of cancer (n = 156), had no information on dietary information (n = 189), had implausible energy intake (<500 kcal/day or >5000 kcal/day; n = 52), had missing information on confounding variables (n = 74), and had no information on SNP rs1801260 (n = 2230) were excluded, and the final analytic sample was 3608 (1839 men and 1769 women). The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Inha University on 31 January 2020 (IRB No. 2001291A).

#### 2.2. Dietary Assessment

Dietary data were obtained by well-trained interviewers using a 103-item semiquantitative food frequency questionnaire (FFQ) at baseline. In order to assess the usual dietary intake of the Korean adults who participated in the KoGES, this validated FFQ was developed and used [10]. All study participants were asked how often they consumed each food item during the previous 12 months. A total of nine frequency responses, ranging from never or almost never to  $\geq$ 3 times per day, were collected [10]. The usual intake of foods and nutrients, including MUFA, was calculated by multiplying the frequency of consumption of each food item and nutrient contents for its corresponding food item utilizing a nutrient database (CAN-Pro 2.0) developed by the Korean Nutrition Society [11]. In the present study, MUFA were assessed from FFQ as a percentage contribution from energy (% energy).

#### 2.3. Assessment of Metabolic Syndrome

Diagnosis of metabolic syndrome was carried out according to guidelines of the National Cholesterol Education Program Adult Treatment Panel III [12] and the International Diabetes Federation [13]. New-onset metabolic syndrome was identified based on the presence of three or more of the following conditions: (1) abdominal obesity (waist circumference  $\geq 90$  cm for men and  $\geq 80$  cm for women); (2) elevated blood pressure (systolic blood pressure  $\geq 130$  mmHg or diastolic blood pressure  $\geq 85$  mmHg or antihypertensive drug use or antihypertensive treatment); (3) elevated fasting blood glucose (FBG)  $\geq 100$  mg/dL or insulin or oral drug therapy; (4) elevated triglyceride levels (fasting triglyceride  $\geq 150$  mg/dL); and (5) low high-density lipoprotein (HDL) cholesterol levels (fasting HDL-cholesterol < 40 mg/dL for men and <50 mg/dL for women). In the survival analysis, survival time for individuals who reported any diagnosis of metabolic syndrome during the follow-up period was defined as the time between the baseline and the date

of the new onset of metabolic syndrome. Participants who did not acquire metabolic syndrome were censored at the last date of follow-up examination. Survival time was calculated as the time difference between the baseline and the last follow-up.

## 2.4. Genotyping and Imputation

Genomic information was obtained from participants' DNA samples that were isolated from their peripheral blood samples. Genetic data were collected utilizing the Korean Biobank Array (Korean Chip, K-CHIP) through the K-CHIP consortium [14]. K-CHIP, including approximately 833,535 SNPs specific to the Korean population, was designed by the Center for Genome Science, Korea National Institute of Health [14]. For standard quality control procedures, *p* Value for Hardy–Weinberg equilibrium  $\geq 1.0 \times 10^{-6}$  and call rate  $\geq 95\%$  were used [14]. Genetic data were imputed using Shapeit v2 and IMPUTE v2, with the 1,000 Genomes Project phase 3 reference [14].

### 2.5. Statistical Analyses

Genetic analysis was performed using PLINK (version 1.90 beta, https://www.coggenomics.org/plink/1.9). All analyses were performed separately for men and women. Study participants were categorized into two groups, according to the median value of the percentage of energy acquired from MUFA intake for men and women, respectively. Baseline sociodemographic, clinical, and lifestyle characteristics of the study participants were computed using Chi-square tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables. Using multivariable Cox proportional hazards models, hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of metabolic syndrome were estimated using the CLOCK SNP rs1801260 under a dominant genetic model stratified by MUFA intake. The potential covariates that were entered into the model were age (years), area of residence (Ansung, Ansan), education level [elementary school or lower (<7 years of school completed), middle/high school (7-12 years), college or higher (>12 years)], smoking status (never, former smoker, current smoker), alcohol consumption (g/day), physical activity [metabolic equivalent task (MET)-h/week], body mass index (BMI; kg/m<sup>2</sup>), and family history of diabetes (determined on the basis of self-reports: yes, no). All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, USA). A two-sided p Value of < 0.05, was considered statistically significant.

## 3. Results

Briefly, 1658 of the study population had an incidence of metabolic syndrome during an average of nine years of follow-up. Table 1 presents the sociodemographic, clinical, lifestyle, and genetic characteristics of the study participants at baseline. The characteristics of age, insulin level, glucose level, insulin resistance, triglyceride level, HDL cholesterol level, waist circumference, systolic blood pressure, diastolic blood pressure, BMI, alcohol intake, MET-h/week, region, smoking status, and dietary fat composition all significantly differed by sex (all *p* Values < 0.0001).

Table 1. Sociodemographic, clinical, lifestyle, and genetic characteristics of the study participants at baseline.

	Total ( <i>n</i> = 3608)	Men ( <i>n</i> = 1839)	Women ( <i>n</i> = 1769)	<i>p</i> Value <sup>1</sup>
Age (years)	$50.9\pm8.7$	$51.4\pm8.8$	$50.4\pm8.6$	< 0.0001
Insulin (µIU/mL)	$7\pm4.3$	$6.6\pm3.9$	$7.5\pm4.7$	< 0.0001
Glucose (mg/dL)	$84.3\pm15.6$	$86.8 \pm 17.1$	$81.8 \pm 13.3$	< 0.0001
HOMA-IR	$1.5\pm1.2$	$1.4\pm0.9$	$1.5\pm1.4$	< 0.0001
Triglyceride (mg/dL)	$134.8\pm82$	$151.2\pm99.1$	$117.7\pm54.2$	< 0.0001
HDL-Cholesterol (mg/dL)	$47\pm10.1$	$45.7\pm9.9$	$48.3\pm10.2$	< 0.0001
Waist circumference (cm)	$79.7\pm7.6$	$81.4\pm6.7$	$77.9 \pm 8.1$	< 0.0001
Systolic blood pressure (mmHg)	$116.6\pm16.6$	$118.6\pm16.2$	$114.6\pm16.8$	< 0.0001

	Total ( <i>n</i> = 3608)	Men ( <i>n</i> = 1839)	Women ( <i>n</i> = 1769)	<i>p</i> Value <sup>1</sup>
Diastolic blood pressure (mmHg)	$77.5\pm10.6$	$79.6\pm10.5$	$75.3\pm10.4$	< 0.0001
BMI $(kg/m^2)$	$23.7\pm2.8$	$23.5\pm2.6$	$24\pm2.9$	< 0.0001
Alcohol intake (g/day)	$9.7\pm21.4$	$17.9\pm27.2$	$1.3\pm4.6$	< 0.0001
MET-h/week	$163.7\pm101.8$	$172\pm105.3$	$155.1\pm97.4$	< 0.0001
Region (%)				
Ansung	1495 (41.4%)	712 (38.7%)	783 (44.3%)	0.0007
Ansan	2113 (58.6%)	1127 (61.3%)	986 (55.7%)	
Smoking (%)				
None	2092 (58.0%)	381 (20.7%)	1711 (96.7%)	< 0.0001
Past	596 (16.5%)	581 (31.6%)	15 (0.9%)	
Current	920 (25.5%)	877 (47.7%)	43 (2.4%)	
Dietary fat composition				
Total fat (% of energy)	$13.3\pm5$	$13.9\pm4.9$	$12.7\pm5$	< 0.0001
SFA (% of energy)	$4.4\pm2$	$4.6\pm1.9$	$4.1\pm2.1$	< 0.0001
MUFA (% of energy)	$3.5\pm1.7$	$3.7\pm1.7$	$3.3\pm1.7$	< 0.0001
PUFA (% of energy	$2.2\pm0.8$	$2.2\pm0.8$	$2.2\pm0.8$	0.0045
Total fat (g/day)	$30.6 \pm 17$	$33.1\pm17.3$	$28\pm16.1$	< 0.0001
SFA (g/day)	$10\pm 6.1$	$10.9\pm6.2$	$9\pm5.8$	< 0.0001
MUFA (g/day)	$8.1\pm5.4$	$8.9\pm5.6$	$7.3\pm5$	< 0.0001
PUFA(g/day)	$5.1\pm2.8$	$5.3\pm2.9$	$4.8\pm2.7$	< 0.0001
CLOCK rs1801260 genotype				
AA	2909 (80.6%)	1484 (80.7%)	1425 (80.6%)	0.9583
AG	666 (18.5%)	339 (18.4%)	327 (18.5%)	
GG	33 (0.9%)	16 (0.9%)	17 (0.9%)	

Table 1. Cont.

HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high-density lipoprotein; MET, metabolic equivalent task; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. <sup>1</sup> p Values based on t-tests for continuous variables and Chi-square tests for categorical variables.

The sociodemographic, clinical, and lifestyle characteristics of the study participants at baseline according to the *CLOCK* rs1801260 genotype are presented in Table 2. No statistically significant differences were detected in age, insulin level, glucose level, insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR)], triglyceride level, HDL-cholesterol level, waist circumference, systolic and diastolic blood pressure, MET-h/week, region, smoking status, and dietary fat composition between the *CLOCK* rs1801260 genotypes (AA vs. AG + GG) in men and women, respectively. Men with AA rs1801260 genotype had marginally and significantly higher MET-h/week than those with the AG or GG rs1801260 genotype (p = 0.06).

**Table 2.** Sociodemographic, clinical, and lifestyle characteristics of the study participants at baseline according to the *CLOCK* rs1801260 genotype.

	Men ( <i>n</i> = 1839)						Women ( <i>n</i> = 1769)				
	CLOCK rs1801260					CLOCK rs1801260					
	AA ( <i>n</i> = 1484)		AG + GG (n = 355)			AA $(n = 1425)$		AG + GG (n = 344)			
	Mean	SD	Mean	SD	p Value <sup>1</sup>	Mean	SD	Mean	SD	p Value <sup>1</sup>	
Age (years)	50.7	8.4	50.3	8.2	0.49	50	8.2	49.7	8.3	0.62	
Insulin (µIU/mL)	6.6	4.1	6.4	3	0.34	7.3	4.5	7.6	3.5	0.19	
Glucose (mg/dL)	87.2	17.2	87.7	19.8	0.66	81.4	11.3	82.3	11.4	0.21	
HOMA-IR	1.4	0.9	1.4	0.7	0.58	1.5	0.9	1.6	0.8	0.09	
Triglyceride (mg/dL)	150	101.5	148.3	74.1	0.72	117.4	55.2	117.5	51.4	0.98	
HDL-Cholesterol (mg/dL)	45.7	9.7	45.4	9.7	0.63	48.5	9.8	47.9	10.7	0.34	
Waist circumference (cm)	81.4	6.5	81.4	6.8	0.85	77.8	8	77.8	7.6	0.99	
Systolic blood pressure (mmHg)	117.5	15.1	118.6	15	0.19	114	16.1	113.6	16	0.62	
Diastolic blood pressure (mmHg)	79.3	10.1	79.7	10.2	0.45	75.2	10	74.9	9.7	0.60	
BMI $(kg/m^2)$	23.6	2.6	23.6	2.6	0.91	24	2.9	24	2.6	0.94	

	Men (n = 1839) 					Women ( <i>n</i> = 1769) CLOCK rs1801260				
	AA ( <i>n</i> = 1484)		AG + GG (n = 355)			AA $(n = 1425)$		AG + GG (n = 344)		
	Mean	SD	Mean	SD	p Value <sup>1</sup>	Mean	SD	Mean	SD	p Value <sup>1</sup>
Alcohol intake (g/day)	18	25.3	16.8	29.9	0.45	1.3	4.6	1.4	5.8	0.83
MET-h/week	170.6	103.7	159.3	97	0.06	159.5	100.2	154	89.9	0.32
Region (%)										
Ansung	581	39.2	131	36.9	0.43	640	44.9	143	41.6	0.26
Ansan	903	60.9	224	63.1		785	55.1	201	58.4	
Smoking (%)										
None	301	20.3	80	22.5	0.49	1377	96.6	334	97.1	0.87
Past	466	31.4	115	32.4		12	0.8	3	0.9	
Current	717	48.3	160	45.1		36	2.5	7	2.0	
Dietary fat composition										
Total fat (% of energy)	14.1	4.8	14.3	4.7	0.68	12.8	5.2	12.6	4.7	0.41
SFA (% of energy)	4.7	1.9	4.7	2	0.56	4.2	2.1	4.1	1.9	0.73
MUFA (% of energy)	3.8	1.7	3.9	1.7	0.41	3.4	1.8	3.3	1.6	0.33
PUFA (% of energy	2.3	0.8	2.3	0.8	0.27	2.2	0.8	2.2	0.9	0.53
Total fat (g/day)	33.3	17	34	17.1	0.54	28.4	16.9	27.8	14.1	0.52
SFA (g/day)	11	6.1	11.3	6.4	0.47	9.1	6.1	9.1	5.3	0.86
MUFĀ (g/day)	9	5.4	9.3	5.8	0.31	7.5	5.3	7.2	4.3	0.32
PUFA (g/day)	5.3	2.8	5.5	2.7	0.30	4.9	2.7	4.8	2.9	0.66

Table 2. Cont.

SD, standard deviation; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high-density lipoprotein; MET, metabolic equivalent task; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. <sup>1</sup> *p* Values based on *t*-tests for continuous variables and Chi-square tests for categorical variables.

Table 3 shows the sociodemographic, clinical, and lifestyle characteristics of the study participants at baseline according to the *CLOCK* rs1801260 genotype and dietary MUFA intake. Dietary MUFA intake was divided by median values: 3.5% of total energy for men and 3% of total energy for women. In men, age, HDL-cholesterol, systolic blood pressure, BMI, alcohol intake, and MET-h/week significantly differed across the rs1801260 genotypes and dietary MUFA intake groups (rs1801260 genotype AA and MUFA  $\leq$  3.5% of total energy, rs1801260 genotype AA and MUFA > 3.5% of total energy, rs1801260 genotype AG + GG and MUFA  $\leq$  3.5% of total energy, and rs1801260 genotype AG + GG and MUFA  $\geq$  3.5% of total energy) (all *p* Values < 0.05). In women, age, glucose level, waist circumference, systolic and diastolic blood pressure, alcohol intake, and MET-h/week all significantly differed across the rs1801260 genotypes (all *p* Values < 0.05).

The association between *CLOCK* rs1801260 polymorphisms and the incidence of metabolic syndrome is presented in Table 4. Men who were G carriers (AG + GG) showed a significantly higher incidence of metabolic syndrome compared to AA homozygous subjects (HR, 1.18; 95% CI, 1.00–1.40; *p* Value = 0.047) after controlling for age, region, smoking, alcohol consumption, physical activity, family history of type 2 diabetes, and BMI. There was no significant association between the rs1801260 polymorphism and the incidence of metabolic syndrome in women.

Men ( <i>n</i> = 1839)	rs1801260 AA an of Energy	rs1801260 AA and MUFA $\leq 3.5\%$ of Energy ( <i>n</i> = 719)		rs1801260 AA and MUFA > 3.5% of Energy ( <i>n</i> = 765)		rs1801260 AG + GG and MUFA $\leq$ 3.5% of Energy ( $n = 154$ )		rs1801260 AG + GG and MUFA > 3.5% of Energy ( <i>n</i> = 201)	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	p Value <sup>1</sup>
Age (years)	52.5 <sup>a</sup>	8.7	49 <sup>b</sup>	7.8	51.5 <sup>a</sup>	8.6	49.4 <sup>b</sup>	7.8	< 0.0001
Insulin (μIU/mL)	6.6	4.5	6.6	3.7	6.5	2.9	6.4	3	0.87
Glucose (mg/dL)	86.5	17.2	87.9	17.2	87.1	19.9	88.2	19.7	0.4
HOMA-IR	1.4	1	1.4	0.8	1.4	0.7	1.4	0.7	0.97
Triglyceride (mg/dL)	154.1	113.1	146	89.1	154.4	81	143.6	68.1	0.29
HDL-Cholesterol (mg/dL)	44.9 <sup>b</sup>	9.5	46.4 <sup>a</sup>	9.7	46.1 <sup>ab</sup>	10.7	44.8 <sup>b</sup>	8.8	0.01
Waist circumference (cm)	81 <sup>b</sup>	6.6	81.7 <sup>a</sup>	6.5	81.2 <sup>ab</sup>	6.7	81.6 <sup>ab</sup>	6.9	0.21
Systolic blood pressure (mmHg)	118.7 <sup>a</sup>	15.8	116.3 <sup>b</sup>	14.3	120.3 <sup>a</sup>	14.9	117.4 <sup>ab</sup>	15	0.002
Diastolic blood pressure (mmHg)	79.4	9.8	79.1	10.4	80.1	10.3	79.4	10.2	0.71
BMI $(kg/m^2)$	23.4 <sup>b</sup>	2.6	23.9 <sup>a</sup>	2.6	23.5 <sup>ab</sup>	2.5	23.7 <sup>ab</sup>	2.7	0.004
Alcohol intake (g/day)	14.8 <sup>b</sup>	21.9	21.1 <sup>a</sup>	27.8	19.4 <sup>a</sup>	38.2	14.7 <sup>b</sup>	21.5	< 0.0001
MET-h/week	178.7 <sup>a</sup>	106.4	163.1 <sup>bc</sup>	100.6	154 <sup>bc</sup>	98.5	163.4 <sup>ab</sup>	95.8	0.005
	rs1801260 AA and MUFA $\leq$ 3.5% of energy ( <i>n</i> = 696)		rs1801260 AA and MUFA > $3.5\%$ of energy ( $n = 729$ )		rs1801260 AG + GG and MUFA $\leq 3.5\%$ of energy ( $n = 168$ )		rs1801260 AG + GG and MUFA > 3.5% of energy ( <i>n</i> = 176)		
women ( $n = 1769$ )	Mean	SD	Mean	SD	Mean	SD	Mean	SD	<i>p</i> Value <sup>1</sup>
Age (years)	52.3 <sup>a</sup>	8.6	47.8 <sup>b</sup>	7.1	52.4 <sup>a</sup>	8.7	47.2 <sup>b</sup>	7.1	<0.0001
Insulin (µIU/mL)	7.4	4.8	7.2	4.2	7.8	3.7	7.4	3.3	0.58
Glucose $(mg/dL)$									
	82.1 <sup>a</sup>	13.9	80.8 <sup>b</sup>	7.9	81.4 <sup>ab</sup>	8.8	83.1 <sup>a</sup>	13.4	0.047
HOMA-IR	82.1 <sup>a</sup> 1.5	13.9 1	80.8 <sup>b</sup> 1.4	7.9 0.9	81.4 <sup>ab</sup> 1.6	8.8 0.8	83.1 <sup>a</sup> 1.5	13.4 0.8	0.047 0.35
HOMA-IR Triglyceride (mg/dL)	82.1 <sup>a</sup> 1.5 120.1	13.9 1 62.4	80.8 <sup>b</sup> 1.4 114.9	7.9 0.9 47.2	81.4 <sup>ab</sup> 1.6 122.4	8.8 0.8 45.3	83.1 <sup>a</sup> 1.5 112.9	13.4 0.8 56.3	0.047 0.35 0.12
HOMA-IR Triglyceride (mg/dL) HDL-Cholesterol (mg/dL)	82.1 <sup>a</sup> 1.5 120.1 48.3	13.9 1 62.4 9.6	80.8 <sup>b</sup> 1.4 114.9 48.7	7.9 0.9 47.2 10	81.4 <sup>ab</sup> 1.6 122.4 47.2	8.8 0.8 45.3 11.2	83.1 <sup>a</sup> 1.5 112.9 48.5	13.4 0.8 56.3 10.3	0.047 0.35 0.12 0.37
HOMA-IR Triglyceride (mg/dL) HDL-Cholesterol (mg/dL) Waist circumference (cm)	82.1 <sup>a</sup> 1.5 120.1 48.3 78.9 <sup>ab</sup>	13.9 1 62.4 9.6 8.3	80.8 <sup>b</sup> 1.4 114.9 48.7 76.7 <sup>c</sup>	7.9 0.9 47.2 10 7.5	81.4 <sup>ab</sup> 1.6 122.4 47.2 79.1 <sup>a</sup>	8.8 0.8 45.3 11.2 7.6	83.1 <sup>a</sup> 1.5 112.9 48.5 76.5 <sup>c</sup>	13.4 0.8 56.3 10.3 7.4	0.047 0.35 0.12 0.37 <0.0001
HOMA-IR Triglyceride (mg/dL) HDL-Cholesterol (mg/dL) Waist circumference (cm) Systolic blood pressure (mmHg)	82.1 <sup>a</sup> 1.5 120.1 48.3 78.9 <sup>ab</sup> 115.9 <sup>a</sup>	13.9 1 62.4 9.6 8.3 16.9	80.8 <sup>b</sup> 1.4 114.9 48.7 76.7 <sup>c</sup> 112.3 <sup>b</sup>	7.9 0.9 47.2 10 7.5 15.1	81.4 <sup>ab</sup> 1.6 122.4 47.2 79.1 <sup>a</sup> 115.5 <sup>a</sup>	8.8 0.8 45.3 11.2 7.6 16.6	83.1 <sup>a</sup> 1.5 112.9 48.5 76.5 <sup>c</sup> 111.7 <sup>b</sup>	13.4 0.8 56.3 10.3 7.4 15.1	0.047 0.35 0.12 0.37 <0.0001 <0.0001
HOMA-IR Triglyceride (mg/dL) HDL-Cholesterol (mg/dL) Waist circumference (cm) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)	82.1 <sup>a</sup> 1.5 120.1 48.3 78.9 <sup>ab</sup> 115.9 <sup>a</sup> 76.2 <sup>a</sup>	13.9 1 62.4 9.6 8.3 16.9 10	80.8 <sup>b</sup> 1.4 114.9 48.7 76.7 <sup>c</sup> 112.3 <sup>b</sup> 74.3 <sup>b</sup>	7.9 0.9 47.2 10 7.5 15.1 10	81.4 <sup>ab</sup> 1.6 122.4 47.2 79.1 <sup>a</sup> 115.5 <sup>a</sup> 75.4 <sup>ab</sup>	8.8 0.8 45.3 11.2 7.6 16.6 9.7	83.1 <sup>a</sup> 1.5 112.9 48.5 76.5 <sup>c</sup> 111.7 <sup>b</sup> 74.4 <sup>ab</sup>	13.4 0.8 56.3 10.3 7.4 15.1 9.7	0.047 0.35 0.12 0.37 <0.0001 <0.0001 0.003
HOMA-IR Triglyceride (mg/dL) HDL-Cholesterol (mg/dL) Waist circumference (cm) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) BMI (kg/m <sup>2</sup> )	82.1 <sup>a</sup> 1.5 120.1 48.3 78.9 <sup>ab</sup> 115.9 <sup>a</sup> 76.2 <sup>a</sup> 24	13.9 1 62.4 9.6 8.3 16.9 10 3	80.8 <sup>b</sup> 1.4 114.9 48.7 76.7 <sup>c</sup> 112.3 <sup>b</sup> 74.3 <sup>b</sup> 23.9	7.9 0.9 47.2 10 7.5 15.1 10 2.7	81.4 <sup>ab</sup> 1.6 122.4 47.2 79.1 <sup>a</sup> 115.5 <sup>a</sup> 75.4 <sup>ab</sup> 24.1	8.8 0.8 45.3 11.2 7.6 16.6 9.7 2.5	83.1 <sup>a</sup> 1.5 112.9 48.5 76.5 <sup>c</sup> 111.7 <sup>b</sup> 74.4 <sup>ab</sup> 23.8	13.4 0.8 56.3 10.3 7.4 15.1 9.7 2.8	0.047 0.35 0.12 0.37 <0.0001 <0.0001 0.003 0.77
HOMA-IR Triglyceride (mg/dL) HDL-Cholesterol (mg/dL) Waist circumference (cm) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) BMI (kg/m <sup>2</sup> ) Alcohol intake (g/day)	82.1 <sup>a</sup> 1.5 120.1 48.3 78.9 <sup>ab</sup> 115.9 <sup>a</sup> 76.2 <sup>a</sup> 24 0.8 <sup>c</sup>	$ 13.9 \\ 1 \\ 62.4 \\ 9.6 \\ 8.3 \\ 16.9 \\ 10 \\ 3 \\ 2.6 \\ $	80.8 <sup>b</sup> 1.4 114.9 48.7 76.7 <sup>c</sup> 112.3 <sup>b</sup> 74.3 <sup>b</sup> 23.9 1.8 <sup>a</sup>	$7.9 \\ 0.9 \\ 47.2 \\ 10 \\ 7.5 \\ 15.1 \\ 10 \\ 2.7 \\ 5.8 $	81.4 <sup>ab</sup> 1.6 122.4 47.2 79.1 <sup>a</sup> 115.5 <sup>a</sup> 75.4 <sup>ab</sup> 24.1 1 <sup>b</sup>	8.8 0.8 45.3 11.2 7.6 16.6 9.7 2.5 3.6	83.1 <sup>a</sup> 1.5 112.9 48.5 76.5 <sup>c</sup> 111.7 <sup>b</sup> 74.4 <sup>ab</sup> 23.8 1.7 <sup>ab</sup>	13.4 0.8 56.3 10.3 7.4 15.1 9.7 2.8 7.2	$\begin{array}{c} 0.047\\ 0.35\\ 0.12\\ 0.37\\ < 0.0001\\ < 0.0001\\ 0.003\\ 0.77\\ 0.0002 \end{array}$

**Table 3.** Sociodemographic, clinical, and lifestyle characteristics of the study participants at baseline according to the *CLOCK* rs1801260 genotype and dietary monounsaturated fatty acid (MUFA) intake.

HOMA-IR, homeostatic model assessment of insulin resistance; MET, metabolic equivalent task; SD, standard deviation.  $^{1} p$  Value based on one-way ANOVA test.  $^{abc}$  Bonferroni post hoc test: means with the same letter indicate no significant difference. Any difference between two means carrying different letters is significant (p Value < 0.05).

	Person-Years	Cases/Total	HR	(95% CI)	p Value
<b>Men (</b> <i>n</i> <b>= 1839)</b> rs1801260					
AG + GG	3463	178/355	1.18	(1.00-1.40)	0.047
AA	15,069	671/1484	1.00		
Women ( <i>n</i> = 1769) rs1801260 AG + GG AA	3553 14,991	163/344 646/1425	1.13 1.00	(0.96–1.35)	0.15

Table 4. Hazard ratios (HR)<sup>1</sup> for metabolic syndrome depending on the CLOCK rs1801260 genotype.

HR, hazard ratio; CI, confidence interval. <sup>1</sup> Adjusted for age (in years, continuous), region (Ansung, Ansan), smoking (none, past, current), alcohol intake (g/day), metabolic equivalent (MET)-h/week (continuous), family history of type 2 diabetes (yes/no), and BMI (in kg/m<sup>2</sup>, continuous).

We analyzed the modulation of the *CLOCK* rs1801260 polymorphisms and the incidence of metabolic syndrome stratified by dietary MUFA intake (Table 5). We observed that men who were G carriers (AG + GG) with a MUFA intake  $\leq$  3.5% of total energy had a significantly higher incidence of metabolic syndrome than men with the AA genotype and MUFA intake > 3.5% of total energy (HR, 1.42; 95% CI, 1.23–1.81; *p* Value = 0.004) after adjustment for covariates. No significant associations between *CLOCK* rs1801260 polymorphisms, dietary MUFA intake, and the incidence of metabolic syndrome were observed in women.

**Table 5.** Hazard ratios (HR)<sup>1</sup> for metabolic syndrome depending on the *CLOCK* rs1801260 genotype and dietary monounsaturated fatty acid (MUFA) intake.

	Person-Years	Cases/Total	HR	(95% CI)	p Value	p Interaction
Men ( <i>n</i> = 1839)						
AA and MUFA $\leq$ 3.5% of energy	7175	327/719	1.07	(0.91 - 1.25)	0.40	0.24
AA and MUFA $> 3.5\%$ of energy	7894	344/765	1.00			
AG + GG and MUFA $\leq$ 3.5% of energy	1405	84/154	1.42	(1.12 - 1.81)	0.004	
AG + GG and MUFA > 3.5% of energy	2058	94/201	1.09	(0.86 - 1.37)	0.48	
Women ( <i>n</i> = 1769)						
AA and MUFA $\leq$ 3% of energy	6984	357/696	1.01	(0.86 - 1.20)	0.86	0.96
AA and MUFA $> 3\%$ of energy	8007	289/729	1.00			
AG + GG and MUFA $\leq$ 3% of energy	1625	90/168	1.16	(0.91 - 1.47)	0.24	
AG + GG and MUFA > 3% of energy	1928	73/176	1.13	(0.87 - 1.46)	0.36	

HR, hazard ratio; CI, confidence interval. <sup>1</sup> Adjusted for age (in years, continuous), region (Ansung, Ansan), smoking (none, past, current), alcohol intake (g/day), metabolic equivalent (MET)-h/week (continuous), family history of type 2 diabetes (yes/no), and BMI (in kg/m<sup>2</sup>, continuous).

#### 4. Discussion

In this prospective cohort study, we observed an association between the minor allele carriers of the G allele (AG + GG) of CLOCK rs1801260 and the incidence of metabolic syndrome in Korean men. Previous findings have reported that CLOCK polymorphisms are associated with metabolic-related biomarkers. Subjects with the major allele had higher insulin sensitivity, lower insulin resistance and lower plasma insulin level compared with subjects who were carriers of the minor allele [3]. Similarly, in a study in which the association of *CLOCK* polymorphisms with metabolic syndrome was investigated in 1100 participants in the Genetics of Lipid Lowering Drugs and Diet Network study, GG carriers of rs1801260 in the study population had significantly increased BMI, systolic blood pressure, fasting insulin level, and HOMA-IR compared with those with AG or AA genotype [15]. Consistent with previous findings, when the saturated fatty acid (SFA) intake was  $\geq$ 11.8%, subjects with the rs1801260 GG genotype had significantly higher waist circumference than subjects with the AG or AA genotype [15]. In a cohort study of 356 elderly subjects, elderly individuals with the rs1801260 GG genotype had significantly higher fasting glucose levels than those with the AA or AG genotype [16]. CLOCK rs1801260 was associated with chronotype [17,18], while other studies did not support

this association [19,20]. In a population-based sample of 410 normal middle-aged adults, subjects with the G allele of rs1801260 preferred "eveningness" over "morningness" [17]. In middle-aged Korean adults, the evening chronotype was associated with a higher incidence of diabetes and lower lean mass in men [21]. Previous findings suggest that the evening type is associated with a greater risk for sleep curtailment, and a growing body of evidence suggests that poor-quality sleep and sleep curtailment are associated with an increased risk of obesity [22–24].

We hypothesized that *CLOCK* genetic polymorphisms are associated with the incidence of metabolic syndrome modulated by dietary MUFA intake. When stratified by dietary MUFA intake, we found that men with carriers of the minor G allele of rs1801260 (AG + GG) and MUFA  $\leq$  3.5% of total energy had a higher incidence of metabolic syndrome than those with the major allele of rs1801260 (AA) and MUFA > 3.5%. No significant relationship was found for MUFA > 3.5% of the total energy. Garaulet et al. [15] reported that when MUFA intake was  $\geq$ 13.2% of the total energy, carriers of the G allele (GG + GC) of rs4580704 had significantly lower plasma glucose concentration and HOMA-IR than non-carriers. When SFA intake was  $\geq$ 11.8%, minor allele carriers had a larger waist circumference than non-carriers. A protective effect of MUFA on metabolic syndrome, lipid profile, and blood pressure has been reported [8,25,26]. MUFA-rich diets are associated with the inhibition of low-density lipoprotein particle oxidation [27].

Furthermore, dietary MUFA promotes peroxisome proliferator-activated receptor alpha, which enhances fatty acid oxidation and inhibits lipogenesis by suppressing sterol regulatory element binding protein, which, in turn, lowers triglyceride levels in blood [28]. Consistent with these findings, in this study, an increasing incidence of metabolic syndrome was found in men with low intake of MUFA and carrying a minor allele of rs1801260. In contrast, no such significant association could be found in women. Further, women with G minor alleles of rs1801260 did not show increased incidence of metabolic syndrome. The lack of associations in women may be partially due to masking effect by other strong risk factors such as decreased estradiol and estrone level in women who were in postmenopausal stage [29] in the present study. Future studies are warranted to elucidate the potential role of sex on the association *CLOCK* gene polymorphisms and the incidence of metabolic syndrome.

*CLOCK* rs1801260 polymorphisms have been suggested to be associated with obesity [4,15,30–33], depression [16] and Parkinson's disease [34]. Among obese patients, individuals with the G minor alleles of rs1801260 (GG + AG) showed higher BMI values compared with those carrying the major allele (AA), and obese patients with the minor allele of rs1801260 were resistant to losing weight compared to those with the major allele [31]. This suggests that the *CLOCK* rs1801260 polymorphism is associated with body weight reduction. In school-age girls with the G allele, carriers of rs1801260 showed increased BMI z-scores at baseline and follow-up [30]. Elderly subjects with the minor allele (rs1801260 GG type) had lower scores on the depression geriatric scale, predisposing greater risk for depression [16]. In a Chinese population, *CLOCK* rs1801260 polymorphism was associated with an increased risk of Parkinson's disease [34].

This study has several limitations and strengths. The limitation was that this study was conducted on a Korean population, and this finding may not be applicable to other race/ethnicities or populations. Replication studies are warranted to confirm the findings of this study. Despite this limitation, this study has several strengths. To the best of our knowledge, this is the first study to investigate the effect of *CLOCK* polymorphisms on the incidence of metabolic syndrome modulated by dietary MUFA intake in Korean adults. Second, the study utilized a prospective cohort study design to examine the cause–effect relationship of *CLOCK* polymorphisms and the incidence of metabolic syndrome modulated by dietary MUFA intake. Lastly, numerous important confounders, such as physical activity, smoking, drinking habits, and BMI were controlled in the present study.

In conclusion, we found an association between the presence of the minor alleles (AG + GG) of *CLOCK* rs1801260 and low dietary MUFA intake with the incidence of

metabolic syndrome in Korean men. The incidence of metabolic syndrome was increased in men who were G carriers (AG + GG) by 42% after adjustment for confounders. These results suggest the significance of *CLOCK* genes in metabolic syndrome risk and the modulating role of dietary MUFA intake. This provides new insights into the underlying mechanisms connecting the circadian system, dietary factors, and metabolic syndrome.

**Author Contributions:** D.S. conceptualized the study design, conducted statistical analyses, interpreted the data, wrote the first draft of the manuscript, and revised the manuscript. K.-W.L. interpreted the data, supervised all aspects of the implementation, provided scientific advice, and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (grant No. 2020R1G1A1004940).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Inha University on 31 January 2020 (IRB No. 2001291A).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The dataset used in this study (Ansan-Ansung Cohort Study of the KoGES) can be provided after review and evaluation of research plan by the Korea National Institute of Health, Korea Centers for Disease Control and Prevention (http://nih.go.kr/contents.es?mid=a5 0401010400).

Acknowledgments: This study was conducted with biosources from the National Biobank of Korea, the Centers for Disease Control and Prevention, Republic of Korea (KBN-2020-016).

Conflicts of Interest: The authors declare no competing interests.

## References

- 1. Turek, F.W.; Joshu, C.; Kohsaka, A.; Lin, E.; Ivanova, G.; McDearmon, E.; Laposky, A.; Losee-Olson, S.; Easton, A.; Jensen, D.R.; et al. Obesity and metabolic syndrome in circadian Clock mutant mice. *Science* **2005**, *308*, 1043–1045. [CrossRef]
- Yang, X.; Downes, M.; Yu, R.T.; Bookout, A.L.; He, W.; Straume, M.; Mangelsdorf, D.J.; Evans, R.M. Nuclear receptor expression links the circadian clock to metabolism. *Cell* 2006, 126, 801–810. [CrossRef]
- Garcia-Rios, A.; Gomez-Delgado, F.J.; Garaulet, M.; Alcala-Diaz, J.F.; Delgado-Lista, F.J.; Marin, C.; Rangel-Zuñiga, O.A.; Rodriguez-Cantalejo, F.; Gomez-Luna, P.; Ordovas, J.M.; et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. *Chronobiol. Int.* 2014, *31*, 401–408. [CrossRef]
- 4. Scott, E.; Carter, A.; Grant, P. Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man. *Int. J. Obes.* **2008**, *32*, 658–662. [CrossRef]
- 5. Rudic, R.D.; McNamara, P.; Curtis, A.M.; Boston, R.C.; Panda, S.; Hogenesch, J.B.; Fitzgerald, G.A. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. *PLoS Biol.* **2004**, *2*, e377. [CrossRef]
- Marcheva, B.; Ramsey, K.M.; Buhr, E.D.; Kobayashi, Y.; Su, H.; Ko, C.H.; Ivanova, G.; Omura, C.; Mo, S.; Vitaterna, M.H.; et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. *Nature* 2010, 466, 627–631. [CrossRef]
- Valladares, M.; Obregón, A.M.; Chaput, J.-P. Association between genetic variants of the clock gene and obesity and sleep duration. J. Physiol. Biochem. 2015, 71, 855–860. [CrossRef]
- 8. Gillingham, L.G.; Harris-Janz, S.; Jones, P.J.H. Dietary Monounsaturated Fatty Acids Are Protective Against Metabolic Syndrome and Cardiovascular Disease Risk Factors. *Lipids* 2011, *46*, 209–228. [CrossRef]
- 9. Kim, Y.; Han, B.G. Cohort Profile: The Korean Genome and Epidemiology Study (KoGES) Consortium. *Int. J. Epidemiol.* 2017, 46, e20. [CrossRef]
- 10. Ahn, Y.; Kwon, E.; Shim, J.; Park, M.; Joo, Y.; Kimm, K.; Park, C.; Kim, D. Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. *Eur. J. Clin. Nutr.* **2007**, *61*, 1435–1441. [CrossRef]
- 11. Korean Nutrition Society. *Computer Aided Nutritional Analysis Program 4.0 for Professionals;* The Korean Nutrition Society: Seoul, Korea, 2011.
- 12. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 2001, 285, 2486–2497.

- 13. Alberti, K.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.-C.; James, W.P.T.; Loria, C.M.; Smith, S.C., Jr. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. *Circulation* 2009, 120, 1640–1645.
- Moon, S.; Kim, Y.J.; Han, S.; Hwang, M.Y.; Shin, D.M.; Park, M.Y.; Lu, Y.; Yoon, K.; Jang, H.-M.; Kim, Y.K. The Korea biobank array: Design and identification of coding variants associated with blood biochemical traits. *Sci. Rep.* 2019, *9*, 1–11. [CrossRef] [PubMed]
- Garaulet, M.; Lee, Y.C.; Shen, J.; Parnell, L.D.; Arnett, D.K.; Tsai, M.Y.; Lai, C.Q.; Ordovas, J.M. CLOCK genetic variation and metabolic syndrome risk: Modulation by monounsaturated fatty acids. *Am. J. Clin. Nutr.* 2009, *90*, 1466–1475. [CrossRef] [PubMed]
- Pagliai, G.; Sofi, F.; Dinu, M.; Sticchi, E.; Vannetti, F.; Molino Lova, R.; Ordovàs, J.M.; Gori, A.M.; Marcucci, R.; Giusti, B.; et al. CLOCK gene polymorphisms and quality of aging in a cohort of nonagenarians—The MUGELLO Study. *Sci. Rep.* 2019, *9*, 1472. [CrossRef] [PubMed]
- 17. Katzenberg, D.; Young, T.; Finn, L.; Lin, L.; King, D.P.; Takahashi, J.S.; Mignot, E. A CLOCK polymorphism associated with human diurnal preference. *Sleep* **1998**, *21*, 569–576. [CrossRef]
- Mishima, K.; Tozawa, T.; Satoh, K.; Saitoh, H.; Mishima, Y. The 3111T/C polymorphism of hClock is associated with evening preference and delayed sleep timing in a Japanese population sample. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 2005, 133b, 101–104. [CrossRef] [PubMed]
- 19. Chang, A.M.; Buch, A.M.; Bradstreet, D.S.; Klements, D.J.; Duffy, J.F. Human diurnal preference and circadian rhythmicity are not associated with the CLOCK 3111C/T gene polymorphism. *J. Biol. Rhythms* **2011**, *26*, 276–279. [CrossRef] [PubMed]
- Robilliard, D.L.; Archer, S.N.; Arendt, J.; Lockley, S.W.; Hack, L.M.; English, J.; Leger, D.; Smits, M.G.; Williams, A.; Skene, D.J.; et al. The 3111 Clock gene polymorphism is not associated with sleep and circadian rhythmicity in phenotypically characterized human subjects. J. Sleep Res. 2002, 11, 305–312. [CrossRef]
- Yu, J.H.; Yun, C.H.; Ahn, J.H.; Suh, S.; Cho, H.J.; Lee, S.K.; Yoo, H.J.; Seo, J.A.; Kim, S.G.; Choi, K.M.; et al. Evening chronotype is associated with metabolic disorders and body composition in middle-aged adults. *J. Clin. Endocrinol. Metab.* 2015, 100, 1494–1502. [CrossRef]
- 22. Cappuccio, F.P.; Taggart, F.M.; Kandala, N.B.; Currie, A.; Peile, E.; Stranges, S.; Miller, M.A. Meta-analysis of short sleep duration and obesity in children and adults. *Sleep* 2008, *31*, 619–626. [CrossRef]
- 23. Patel, S.R.; Hu, F.B. Short sleep duration and weight gain: A systematic review. Obesity 2008, 16, 643–653. [CrossRef] [PubMed]
- 24. Chen, X.; Beydoun, M.A.; Wang, Y. Is sleep duration associated with childhood obesity? A systematic review and meta-analysis. *Obesity* **2008**, *16*, 265–274. [CrossRef] [PubMed]
- 25. Erkkilä, A.T.; Matthan, N.R.; Herrington, D.M.; Lichtenstein, A.H. Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD. *J. Lipid Res.* **2006**, *47*, 2814–2819. [CrossRef] [PubMed]
- Alonso, Á.; Ruiz-Gutierrez, V.; Martínez-González, M.Á. Monounsaturated fatty acids, olive oil and blood pressure: Epidemiological, clinical and experimental evidence. *Public Health Nutr.* 2006, 9, 251–257. [CrossRef] [PubMed]
- Lapointe, A.; Couillard, C.; Lemieux, S. Effects of dietary factors on oxidation of low-density lipoprotein particles. J. Nutr. Biochem. 2006, 17, 645–658. [CrossRef] [PubMed]
- 28. Assy, N.; Nassar, F.; Nasser, G.; Grosovski, M. Olive oil consumption and non-alcoholic fatty liver disease. *World J. Gastroenterol. WJG* **2009**, *15*, 1809. [CrossRef] [PubMed]
- De Padua Mansur, A.; Silva, T.C.; Takada, J.Y.; Avakian, S.D.; Strunz, C.M.; Machado César, L.A.; Mendes Aldrighi, J.; Ramires, J.A. Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. *Sci. World J.* 2012, 2012, 363595. [CrossRef]
- 30. Meng, Y.; Lohse, B.; Cunningham-Sabo, L. Sex modifies the association between the CLOCK variant rs1801260 and BMI in school-age children. *PLoS ONE* **2020**, *15*, e0236991. [CrossRef]
- 31. Garaulet, M.; Corbalán, M.D.; Madrid, J.A.; Morales, E.; Baraza, J.C.; Lee, Y.C.; Ordovas, J.M. CLOCK gene is implicated in weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. *Int J. Obes.* **2010**, *34*, 516–523. [CrossRef]
- 32. Garaulet, M.; Sánchez-Moreno, C.; Smith, C.E.; Lee, Y.C.; Nicolás, F.; Ordovás, J.M. Ghrelin, sleep reduction and evening preference: Relationships to CLOCK 3111 T/C SNP and weight loss. *PLoS ONE* **2011**, *6*, e17435. [CrossRef] [PubMed]
- Galbete, C.; Contreras, R.; Martínez, J.A.; Martínez-González, M.Á.; Guillén-Grima, F.; Marti, A. Physical activity and sex modulate obesity risk linked to 3111T/C gene variant of the CLOCK gene in an elderly population: The SUN Project. *Chronobiol. Int.* 2012, 29, 1397–1404. [CrossRef] [PubMed]
- Lou, F.; Li, M.; Ren, Y.; Luo, X.-G.; Liu, N.; Li, X. CLOCK rs1801260 polymorphism is associated with susceptibility to Parkinson's disease in a Chinese population. *Neurosci. Bull.* 2017, 33, 734–736. [CrossRef] [PubMed]